Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Song, Xiaoyan ^a,b   Jia, Hetang ^b   Jiang, Yuebo ^a   Wang, Liang ^b   Zhang, Yan ^b   Mu, Yiming ^a   Liu, Yu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 309TH HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; GLUCAGON LIKE PEPTIDE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

AGED; ARTERIAL WALL THICKNESS; BLOOD; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; FEMALE; HUMAN; MALE; META ANALYSIS; MIDDLE AGED;

AGED; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL; CHOLESTEROL, LDL; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIGLYCERIDES;

EID: 84933499016     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10202     Document Type: Article

References (56)

1. Danaei G, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 378, 31-40 (2011
2. Green, J. & Feinglos, M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc. Health. Risk. Manag. 4, 743-751 (2008
3. Steinberger, J. & Daniels, S. R. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation. 107, 1448-53 (2003
4. Forst, T., Weber, M. M. & Pfutzner A. Cardiovascular benefits of GLP-1-based therapies in patients with diabetes mellitus type 2: Effects on endothelial and vascular dysfunction beyond glycemic control. Exp. Diabetes. Res. 2012, 635472 (2012
5. Mita, T. & Watada, H. Glucagon like peptide-1 and atherosclerosis. Cardiovas. Hematol. Agents. Medicinal. Chem. 10, 309-318 (2012
6. Petrie, J. R. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc. Diabetol. 12, 130 (2013
7. Holst, J. J., Vilsboll, T. & Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 297, 127-136 (2009
8. Hattori, S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr. J. 58, 69-73 (2011
9. Satoh-Asahara, N., et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 62, 347-351 (2013
10. Liu, L., et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60, 833-841 (2012
11. Fadini, G.P., et al. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic. Res. Cardiol. 108, 313 (2013
12. Rieg, T., et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Renal. Physiol. 303, F963-F971 (2011
13. Ayaori, M., et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J. Am. Heart. Assoc 2, e003277. (2013
14. Barbieri, M., et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 227, 349-354 (2013
15. Bergenstal, R.M., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 376, 431-9 (2010
16. Bunck, M.C., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes. Care. 33, 1734-1737 (2010
17. Courreges, J.P., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med. 25, 1129-1131 (2008
18. Derosa, G., et al. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes. Diabet. Med. 31, 1515-23 (2014
19. Forst, T., et al. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet. Med. 29, 1115-1118 (2012
20. Irace, C., et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab. Vasc. Dis. Res. 10, 72-77 (2013
21. Ishikawa, S., et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am. J. Cardiol. 114, 384-388 (2014
22. Juntti-berggren, L., et al. The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients. Diadetes. Care. 19, 1200-1206 (1996
23. Kaku, K., Itayasu, T., Hiroi, S., Hirayama, M. & Seino, Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-Term extension study. Diabetes. Obes. Metab. 13, 1028-1035 (2011
24. Kaku, K., Rasmussen, M. F., Clauson, P. & Seino, Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes. Obes. Metab. 12, 341-347 (2010
25. Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J. M., Katz, H. & Bank, A.J. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc. Diabetol. 11, 64 (2012
26. Makdissi, A., et al. Sitagliptin exerts an antinflammatory action. J. Clin. Endocrinol. Metab. 97, 3333-3341 (2012
27. Matikainen, N., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 49, 2049-2057 (2006
28. Nakamura, K., et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc. Diabetol. 13, 110 (2014
29. Nandy, D., et al. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab. Vasc. Dis. Res. 11, 419-30 (2014
30. Nauck, M., et al. Long-Term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes. Metab. 15, 204-212 (2013
31. Seino, Y., Rasmussen, M.F., Nishida, T. & Kaku, K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr. Med. Res. Opin. 26, 1013-1022 (2010
32. Suzuki, K., et al. Sitagliptin improves vascular endothelial function in Japanese type 2 diabetes patients without cardiovascular disease. J. Diabetes. Mellitus 2, 338-345 (2012
33. Hopkins, N.D., et al. Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients. Diabetes Obes. Metab. 15, 770-773 (2013
34. Inoue, K., et al. Long-Term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol. Metab. Syndr. 6, 95 (2014
35. Kubota, Y., et al. The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes. J. Korean. Med. Sci. 27, 1364-1370 (2012
36. Rizzo, M., et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc. Diabetol. 13, 49 (2014
37. Ceriello, A., Esposito, K., Testa, R., Bonfigli, A.R., Marra, M., et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care 34, 697-702 (2011
38. Ceriello, A., et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care 37, 1938-1943 (2014
39. Ceriello, A., et al. Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes. Diabetes. Care. 36, 4104-4108 (2013a
40. Ceriello, A., et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes. Care. 36, 2346-2350 (2013b
41. Ha, S.J., et al. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler. Thromb. Vasc. Biol. 32, 474-480 (2012
42. Noda, Y., et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc. Diabetol. 12, 8 (2013
43. Nystrom, T., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Lancet. Diabetes. Endocrinol. 2, 691-700 (2014
44. Sivertsen, J., Rosenmeier, J., Holst, J. J. & Vilsboll, T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 9, 209-222 (2012
45. Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R.,& Joyner, M. J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab. 293, E1289-95 (2007
46. Subaran, S. C., et al. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin. Sci. (Lond). 127, 163-70 (2014
47. Aminbakhsh A.,& Mancini G. B. Carotid intima media thickness measurements: What defines an abnormality? A systematic review. Clin. Invest. Med. 22, 149-157 (1999
48. Cheng, J. M., et al. Relation of c-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS Study). Am. J. Cardiol. 114, 1497-503 (2014
49. Ridker, P. M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol. 49, 2129-38 (2007
50. Cybulsky, M. I., Gimbrone, M. A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251, 788-791(1991
51. Couffinhal, T., Duplaa, C., Moreau, C., Lamaziere, J. M. & Bonnet, J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ. Res. 74, 225-234 (1994
52. Liu, H., Dear, A. E., Knudsen, L. B. & Simpson, R. W. A long-Acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol. 201, 59-66 (2009
53. Ashley, K.E., Galla, J.M. & Nicholls, S.J. Brain natriuretic peptides as biomarkers for atherosclerosis. Prev. Cardiol. 11, 172-176 (2008
54. Svensson, P., de Faire, U., Niklasson, U., Hansson, L.O. & Ostergren, J. Plasma NT-pro-BNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood. Press. 14, 99-106 (2005
55. Jin, Q., et al. Levels of brain natriuretic peptide are associated with peripheral arterial disease in subjects with type-2 diabetes mellitus. BMC Endocrine Disorders 14, 27 (2014
56. Blaha, M., et al. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol. Res. 53, 273-278 (2004